Cyclooxygenase activity is increased in platelets from psoriatic patients.
The aim of the present study was to ascertain the relationship between in vitro hyper-aggregability and alterations in arachidonic acid metabolism in platelets from psoriatic patients. We have studied the response to several concentrations of ADP, collagen, and arachidonic acid of intact platelets from psoriatic patients and normal subjects, with and without irreversible inhibition of platelet cyclooxygenase by aspirin. Apparent kinetic constants (apparent Michaelis constant [Km] and apparent maximum velocity [Vmax]) of cyclooxygenase in platelets from both controls and psoriatic patients were also studied. The maximum percentage and slope of aggregation induced by collagen or sodium arachidonate were significantly greater (p less than 0.05) in platelets from psoriasis patients, whereas lag time was significantly shorter in the psoriasis group in response to arachidonic acid only when compared to controls. Cyclooxygenase pathway blockade inhibited the response to aggregation inducers in the following order: sodium arachidonate greater than collagen greater than ADP. When platelets were pre-treated with aspirin no significant differences were observed between controls and psoriasis patients. We also found a significant increase of the apparent Vmax value (p less than 0.05) for cyclooxygenase activity in platelets from psoriatic patients in comparison with controls. Our results indicate that platelet hyperaggregation in psoriatic patients is related to enhanced cyclooxygenase activity in their platelets.
Vila
L
L
Inflammation and Cell Proliferation Mediators Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Cullaré
C
C
Solá
J
J
Puig
L
L
de Castellarnau
C
C
de Moragas
J M
JM
D000328:Adult; D016718:Arachidonic Acid / Q000378:metabolism; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000201:enzymology*; D002250:Carbon Radioisotopes; D003094:Collagen / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D010974:Platelet Aggregation / Q000187:drug effects; D011451:Prostaglandin-Endoperoxide Synthases / Q000097:blood*; D011565:Psoriasis / Q000201:enzymology* / Q000503:physiopathology; D013928:Thromboxane A2 / Q000378:metabolism
D002250:Carbon Radioisotopes; D016718:Arachidonic Acid; D013928:Thromboxane A2; D003094:Collagen; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin